Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the comparison of blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) between patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:46.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the inclusion and exclusion criteria for participants. This change provides more specific information about the health conditions and prior treatments required for study enrollment.
    Difference
    11%
    Check dated 2024-05-22T21:20:19.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:41:08.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.